Increased TILs, higher TMB, obesity, and uncontrolled blood glucose levels were associated with a decreased risk of progression, whereas tumor HLA-A expression, PIK3CA variants, and the LAR subtype were associated with a greater risk of progression for patients receiving the combination. The gene discussed is HLA-A; the disease is obesity due to melanocortin 4 receptor deficiency.